Phio Pharmaceuticals Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Phio Pharmaceuticals Corp. on November 25, 2025. The report addresses a material event under Item 8.01 (Other Events) regarding the company's clinical development activities.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a clinical trial milestone and does not contain financial statements or performance data.
Material Changes
The primary material event reported is the completion of enrollment in the company's ongoing Phase 1b clinical trial (NCT 06014086) for its INTASYL siRNA Lead Compound, PH-762. This announcement was made via a press release issued on the date of the report.
Guidance, Outlook, and Risks
The filing incorporates a press release by reference but does not include specific forward-looking guidance, management commentary on financial outlook, or detailed risk factors within the body of this 8-K. The completion of enrollment represents a progression in the drug development timeline for PH-762.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for details on the Phase 1b trial design and next steps.
- Confirm the clinical trial status and enrollment numbers via the ClinicalTrials.gov identifier NCT 06014086.
- Review recent quarterly or annual reports (10-Q or 10-K) for the most current financial position, as this 8-K contains no financial data.
- Monitor subsequent filings for data readouts or safety updates from the PH-762 trial.